Skip to main content
$29.21 $0.65 (2.3%)

04:00 PM EDT on 09/26/23

Supernus Pharmaceuticals (NASDAQ:SUPN)

CAPS Rating: 3 out of 5

Current Price $29.21 Mkt Cap $1.6B
Open $28.56 P/E Ratio 40.08
Prev. Close $28.56 Div. (Yield) $0.00 (0.0%)
Daily Range $28.56 - $29.80 Volume 411,003
52-Wk Range $27.26 - $42.09 Avg. Daily Vol. 451,705


How do you think NASDAQ:SUPN will perform against the market?

Add Stock to CAPS Watchlist

All Players

57 Outperform
12 Underperform

All-Star Players

6 Outperform
2 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:SUPN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

crashavoidance (98.95)
Submitted July 29, 2015

Already done well with this but believe still some good upside if the two drugs still in development pan out (so far looks good but longer term / higher risk play until actually happens)In the meantime, approach of adding ER (extended release) to… More

XMFBlacknGoldX (< 20)
Submitted June 29, 2012

Man, I wish I got in on this one just a few days earlier (IPO debut). Still, this is about as safe as a red thumb gets. Supernus has shareholders' equity of just $270,000 as of 1Q12, which registers as a fair book value of a whopping $0.0113 per… More

Fools bullish on NASDAQ:SUPN are also bullish on:

Fools bearish on NASDAQ:SUPN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about SUPN.


Member Avatar TMFjimhalley (< 20) Submitted: 3/21/2021 8:49:00 PM : Outperform Start Price: $25.49 NASDAQ:SUPN Score: +5.78

Supernus is already growing revenue and will really take off if the company's ADHD therapy candidate, SPN-812, is approved this year, as expected.


Member Avatar Bigsef77 (48.40) Submitted: 4/29/2020 2:54:00 PM : Outperform Start Price: $48.20 NASDAQ:SUPN Score: -87.20

CNS portfolio acquisition


Member Avatar genedom (91.35) Submitted: 3/14/2019 3:27:37 PM : Outperform Start Price: $37.71 NASDAQ:SUPN Score: -73.58

Good value at 38. Fair value should be 44-50. 4th P3 trial will be positive.


Find the members with the highest scoring picks in SUPN.

No players have picked SUPN yet. Tell us why you think SUPN will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SUPN.